Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 5
2019 5
2020 6
2021 4
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G, Toutouzas K, Tousoulis D, Tsioufis K, Vlachopoulos C. Antonopoulos AS, et al. Eur J Heart Fail. 2022 Sep;24(9):1677-1696. doi: 10.1002/ejhf.2589. Epub 2022 Aug 2. Eur J Heart Fail. 2022. PMID: 35730461 Free article.
AIM: Systematic evidence on the prevalence and clinical outcome of transthyretin amyloidosis (ATTR) is missing. We explored: (i) the prevalence of cardiac amyloidosis in various patient subgroups, (ii) survival estimates for ATTR subtypes, and (iii) the effects of n …
AIM: Systematic evidence on the prevalence and clinical outcome of transthyretin amyloidosis (ATTR) is missing. We explored: (i) the …
Hereditary transthyretin-related amyloidosis.
Finsterer J, Iglseder S, Wanschitz J, Topakian R, Löscher WN, Grisold W. Finsterer J, et al. Acta Neurol Scand. 2019 Feb;139(2):92-105. doi: 10.1111/ane.13035. Epub 2018 Oct 23. Acta Neurol Scand. 2019. PMID: 30295933
Hereditary transthyretin(TTR)-related amyloidosis (ATTRm amyloidosis) is an endemic/non-endemic, autosomal-dominant, early- and late-onset, rare, progressive disorder, predominantly manifesting as length-dependent, small fiber dominant, axonal polyneuropathy …
Hereditary transthyretin(TTR)-related amyloidosis (ATTRm amyloidosis) is an endemic/non-endemic, autosomal-dominant, ea …
Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China.
He X, Tian Z, Guan H, Zhang S. He X, et al. Orphanet J Rare Dis. 2022 Sep 2;17(1):337. doi: 10.1186/s13023-022-02481-9. Orphanet J Rare Dis. 2022. PMID: 36056432 Free PMC article.
BACKGROUND: Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. ...Extracted data included sample size, personal information (sex, age, natural course, family …
BACKGROUND: Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical present …
Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review.
Cristóbal Gutiérrez H, Pelayo-Negro AL, Gómez Gómez D, Martín Vega MÁ, Valero Domínguez M. Cristóbal Gutiérrez H, et al. Eur J Hosp Pharm. 2020 Jul;27(4):194-201. doi: 10.1136/ejhpharm-2018-001823. Epub 2019 Mar 19. Eur J Hosp Pharm. 2020. PMID: 32587078 Free PMC article.
OBJECTIVE: To carry out a systematic review of the literature to analyse the efficacy and safety of treatments available or under investigation for amyloidosis due to mutations in the transthyretin gene (ATTR). METHODS: A bibliographic search was carried out in the followi …
OBJECTIVE: To carry out a systematic review of the literature to analyse the efficacy and safety of treatments available or under investigat …
Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations.
Marques N, Azevedo O, Almeida AR, Bento D, Cruz I, Correia E, Lourenço C, Lopes LR. Marques N, et al. J Am Heart Assoc. 2020 Oct 20;9(19):e016614. doi: 10.1161/JAHA.120.016614. Epub 2020 Sep 24. J Am Heart Assoc. 2020. PMID: 32969287 Free PMC article.
Background The emergence of specific therapies for transthyretin cardiac amyloidosis (CA) warrants the need for a systematic review of the literature. ...
Background The emergence of specific therapies for transthyretin cardiac amyloidosis (CA) warrants the need for a systematic review o …
Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review.
Gonzalez-Duarte A, Valdés-Ferrer SI, Cantú-Brito C. Gonzalez-Duarte A, et al. Clin Auton Res. 2019 Sep;29(Suppl 1):1-9. doi: 10.1007/s10286-019-00630-y. Epub 2019 Aug 31. Clin Auton Res. 2019. PMID: 31473866 Free PMC article.
BACKGROUND: Autonomic dysfunction is a hallmark feature of hereditary ATTR amyloidosis. The aim of this study was to summarize the characteristics and natural history of autonomic dysfunction in patients with hereditary ATTR amyloidosis. ...CONCLUSION: …
BACKGROUND: Autonomic dysfunction is a hallmark feature of hereditary ATTR amyloidosis. The aim of this study was to summarize …
Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.
Xin Y, Hu W, Chen X, Hu J, Sun Y, Zhao Y. Xin Y, et al. Hellenic J Cardiol. 2019 Nov-Dec;60(6):375-383. doi: 10.1016/j.hjc.2019.01.015. Epub 2019 Feb 8. Hellenic J Cardiol. 2019. PMID: 30742933 Free article.
OBJECTIVE: Light-chain amyloidosis and transthyretin-related amyloidosis (wild-type and mutated) are three main types of systemic amyloidosis associated with a clinically relevant cardiac involvement. ...CONCLUSION: Patients diagnosed with light …
OBJECTIVE: Light-chain amyloidosis and transthyretin-related amyloidosis (wild-type and mutated) are three main …
The use of diflunisal for transthyretin cardiac amyloidosis: a review.
Ibrahim M, Saint Croix GR, Lacy S, Fattouh M, Barillas-Lara MI, Behrooz L, Mechanic O. Ibrahim M, et al. Heart Fail Rev. 2022 Mar;27(2):517-524. doi: 10.1007/s10741-021-10143-4. Epub 2021 Jul 16. Heart Fail Rev. 2022. PMID: 34272629 Review.
Transthyretin cardiac amyloidosis (ATTR-CM) is caused by the accumulation of misfolded transthyretin (TTR) protein in the myocardium. ...We included English language studies which assessed the effect of diflunisal in adult patients with ATTR-CM who received diflunisal as p …
Transthyretin cardiac amyloidosis (ATTR-CM) is caused by the accumulation of misfolded transthyretin (TTR) protein in the myocardium. …
Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications.
Penalver J, Ambrosino M, Jeon HD, Agrawal A, Kanjanahattakij N, Pitteloud M, Stempel J, Amanullah A. Penalver J, et al. Curr Cardiol Rev. 2020;16(3):221-230. doi: 10.2174/1573403X15666190722154152. Curr Cardiol Rev. 2020. PMID: 31544701 Free PMC article.
BACKGROUND: There is a growing interest in the observed significant incidence of transthyretin cardiac amyloidosis in elderly patients with aortic stenosis. Approximately, 16% of patients with severe aortic stenosis undergoing aortic valve replacement have transthyretin ca …
BACKGROUND: There is a growing interest in the observed significant incidence of transthyretin cardiac amyloidosis in elderly patient …
Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
Lin X, Yarlas A, Vera-Llonch M, Baranwal N, Biber J, Brown D, Vogt B, Karam C. Lin X, et al. BMC Neurol. 2021 Feb 12;21(1):70. doi: 10.1186/s12883-021-02094-y. BMC Neurol. 2021. PMID: 33579211 Free PMC article.
BACKGROUND: We aimed to compare neuropathic progression rate between hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and other peripheral neuropathies, including diabetic peripheral neuropathy (DPN) and Charcot-Marie-Tooth disease (CMT). ...
BACKGROUND: We aimed to compare neuropathic progression rate between hereditary transthyretin amyloidosis with polyneuropathy …
21 results